Imagine a patient who has just received a stem cell transplant to treat acute myeloid leukemia. They are hoping for a cure, but the risk of the cancer returning remains. Doctors need to know exactly when that risk is highest so they can act quickly. This review looks at whether new ways of checking the immune system can give that warning earlier than usual tests.
The study examined various immune monitoring techniques, including multiparameter flow cytometry and omics-based approaches. These tools aim to look deeper than standard checks to spot early signs of the disease coming back. The goal is to predict relapse and sort patients into different risk groups so treatment can be tailored to their specific needs.
While the potential to improve long-term outcomes is clear, this evidence comes from reviewing past work, not a single large experiment. The review calls for moving beyond simple checks to more complex, integrated methods. Until more direct evidence is available, these advanced tools remain a promising direction for the future rather than a current standard of care.